Single transgenic APP Mouse Models – APP[V717I] mouse model 

The APP[V717I] mouse model primarily models cerebral β-amyloidosis and does not develop full neurofibrillary tangle (NFT) pathology. However, at later disease stages, plaque-associated dystrophic neurites containing hyperphosphorylated murine tau are observed (Tanghe et al., 2010).  

This absence of overt tangle pathology is consistent with other APP transgenic mouse models. Indeed, amyloid-only models robustly reproduce cerebral beta amyloidosis but do not recapitulate the full spectrum of Alzheimer’s disease encompassing tau pathology. To model both amyloid plaques and neurofibrillary tangles in vivo, the incorporation of mutant human tau is required. 

Therefore, for programs targeting combined amyloid-and-tau disease modification, we recommend the APP[V717I]xTau[P301S] mouse model, which recapitulates both extracellular amyloid plaques and progressive tau pathology, providing a more complete Alzheimer’s disease phenotype. 

Learn more about InnoSer’s combined amyloid and tau mouse model here.

Yes, published research has shown that disease modification has been demonstrated in the APP[V717I] mouse model in preclinical studies evaluating the efficacy of BACE1 inhibitors (Jacobsen et al., 2014; Janssens et al., 2021). 

The APP[V717I] mouse model has been widely regarded as a preferred platform for evaluating anti-BACE1 strategies. Because it expresses the human APP London mutation, the model exhibits robust and progressive increases in human Aβ42 levels in a dose-responsive manner. This provides a sensitive and translational system for quantifying reductions in both soluble and insoluble Aβ species following pharmacological intervention. 

BACE1 is the rate-limiting enzyme responsible for the initial cleavage of APP in the amyloidogenic pathway, leading to the generation of amyloid-β (Aβ) peptides. As such, BACE1 inhibition has long been considered a rational disease-modifying strategy aimed at reducing upstream Aβ production. Although several clinical BACE1 inhibitor programs were discontinued due to safety concerns or limited cognitive benefit in symptomatic patients, the approach remains mechanistically relevant, particularly in early-intervention or prevention paradigms where reducing Aβ production may alter disease trajectory. 

If you are advancing a BACE1 inhibitor or other Aβ-lowering therapeutic, reach out to InnoSer’s experts to design a preclinical efficacy study aligned with your development strategy. 

Yes, APP[V717I] mouse model mice demonstrate measurable impairments in spatial learning and memory. In the Morris Water Maze (MWM) probe test, 6-month-old transgenic animals show clear deficits compared to non-transgenic controls. Specifically, APP[V717I] mice display a reduced annulus crossing index (fewer crossings over the former platform location), decreased time spent in the target quadrant, and increased latency to reach the former platform position, indicating impaired spatial reference memory.  

As an alternative in the APP[V717I] mouse model, synaptic and memory-related deficits can be evaluated using electrophysiological readouts using ex vivo brain slices, such as hippocampal long-term potentiation (LTP), which provide sensitive measures of synaptic plasticity that can serve as a proxy measure for memory deficits in the APP mouse model. Indeed, electrophysiological assessment in ex vivo hippocampal slices reveals LT in the CA1 region at 8 months of age. 

However, for programs where cognitive improvement is a primary endpoint, InnoSer’s APP[V717I]xPS1[A246E] mouse model  may offer greater sensitivity, as this model demonstrates clear spatial memory deficits in the Morris water maze along with documented compound-mediated rescue effects (see also figures 1 and 2 of Easton et al., 2013).  

Reach out to InnoSer’s study experts to discuss including cognitive readouts in your preclinical efficacy study now.

In InnoSer’s APP[V717I] mouse model, age-dependent vascular amyloid deposition consistent with cerebral amyloid angiopathy (CAA) is observed at later stages of disease progression. From approximately 15–18 months of age, amyloid deposits accumulate within cerebral vessel walls, affecting multiple vessels per coronal brain section. With advancing age, vascular amyloid pathology progresses to vessel wall damage, aneurysm formation, and microhemorrhages (around 25–30 months), recapitulating key aspects of vascular amyloidosis described in Alzheimer’s disease (See also Figure 5 of van Dorpe et al., 2000). These findings are consistent with observations reported in the original characterization of the model. 

In parallel, APP[V717I] mice exhibit an age-dependent decrease in the CSF Aβ42/Aβ40 ratio, mirroring biomarker dynamics observed in human AD. This decline temporally coincides with extensive parenchymal and vascular amyloid deposition from approximately 15 months onward. 

In recent years, interest in CAA has grown markedly as clinical trial outcomes have highlighted vascular amyloid as a potential driver of treatment-related adverse events, including amyloid-related imaging abnormalities (ARIA). Consequently, CAA has emerged as an important target for mechanistic studies and for the preclinical evaluation of anti-amyloid therapies, particularly immunotherapies and approaches aimed at improving vascular amyloid clearance. 

Although the APP[V717I] (London) mouse model recapitulates key features of late-stage cerebral amyloid angiopathy, vascular amyloid deposition typically emerges from approximately 15–18 months of age. Therefore, for programs specifically investigating earlier-onset CAA, ARIA-related mechanisms, or microbleeds within a shorter experimental timeline, InnoSer’s APP[V717I]xPS1[A246E] mouse model may offer strategic advantages, as CAA develops earlier (from approximately 8 months of age).

Reach out to our team to explore how InnoSer can support the preclinical assessment of cerebral amyloid angiopathy (CAA) and amyloid-related imaging abnormalities (ARIA).